A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland
Patient experiences of using subcutaneous CGRP mAbs in Finland showed improvements in several migraine-related factors, supporting the potential for CGRP mAbs to improve the quality of life of adults with migraine.
Authors
- Camilla Kristine Appel (ORCID: https://orcid.org/0000-0002-2903-7152)
- Lill‐Brith von Arx (ORCID: https://orcid.org/0000-0002-7170-6268)
- Cash Casey (ORCID: https://orcid.org/0000-0001-8702-4547)
- Timo T. Purmonen (ORCID: https://orcid.org/0000-0001-7794-7495)
- Ilona Iso‐Mustajärvi (ORCID: https://orcid.org/0009-0008-7429-3279)
- Essi J Peltonen (ORCID: https://orcid.org/0000-0002-5782-3089)
- Nirjharini Patel
- Mari Pölkki (ORCID: https://orcid.org/0009-0003-4798-1512)
- Elisa K Suvanen (ORCID: https://orcid.org/0009-0001-5255-4115)
Institutions
- Herlev Hospital (DK)
- Eli Lilly (United Kingdom) (GB)
- Orion Corporation (Finland) (FI)
Publication Details
- Journal
- Pain and Therapy
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1007/s40122-025-00719-5
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Eli Lilly and Company